MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Halozyme Therapeutics Company Profile (NASDAQ:HALO)

Consensus Ratings for Halozyme Therapeutics (NASDAQ:HALO) (?)
Ratings Breakdown: 1 Sell Rating(s), 8 Buy Rating(s)
Consensus Rating:Buy (Score: 2.78)
Consensus Price Target: $17.84 (77.20% upside)

Analysts' Ratings History for Halozyme Therapeutics (NASDAQ:HALO)
Show:
DateFirmActionRatingPrice TargetActions
5/10/2016Wells FargoReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/10/2016Canaccord GenuityReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/10/2016Jefferies GroupReiterated RatingSell$6.75View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$22.00 -> $20.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/24/2016BarclaysLower Price TargetOverweight$27.00 -> $16.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/26/2016Piper JaffrayReiterated RatingOverweight$24.00 -> $20.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/18/2015Citigroup Inc.Initiated CoverageBuy$25.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/22/2015JPMorgan Chase & Co.Boost Price TargetOverweight$20.00 -> $25.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/1/2015MLV & Co.Reiterated RatingBuy$20.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/20/2015BMO Capital MarketsSet Price TargetBuy$26.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 5/26/2014 forward)
            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha